Science Corporation Implants Wireless Retinal Prosthesis in First Stargardt Patient During Clinical Trial

San Francisco neurotechnology pioneer Science Corporation achieved an extraordinary clinical milestone on Thursday, announcing the successful surgical implantation of its PRIMA retinal prosthesis in its first patient suffering from advanced Stargardt disease. The delicate two-hour microsurgical procedure, conducted at Sydney Eye Hospital in Australia, successfully positioned a microscopic photovoltaic subretinal microchip directly beneath the patient's damaged central macula. Company neural engineering directors confirmed the surgical success from their laboratory facility in San Francisco, California.

Stargardt disease is an inherited genetic condition that causes progressive, irreversible loss of photoreceptor cells, stripping young adults of central visual acuity while preserving peripheral vision. Science Corporation's PRIMA device consists of a tiny wireless chip containing hundreds of independent light-sensitive pixels powered by invisible near-infrared light projected from specialized augmented reality eyeglasses. The chip converts projected visual scenes into localized electrical impulses that directly stimulate surviving bipolar and retinal ganglion cells, transmitting functional visual data through the optic nerve to the brain.

Ophthalmic surgeons, biomedical engineers, and vision loss advocates worldwide celebrated the clinical achievement as a monumental advance for bioelectronic medicine. Patient advocacy groups emphasized that restoring the ability to read printed text, recognize facial expressions, and navigate unfamiliar environments represents life-changing independence for individuals afflicted with severe macular degeneration. Neuroscientists commended the surgical team for achieving stable subretinal tissue integration without triggering mechanical inflammation or neural signal degradation across sensitive ocular tissues.

The federal regulatory health commission and clinical ethics committee monitored post-operative assessments, reporting that the patient recovered uneventfully and has commenced visual rehabilitation training. Science Corporation chief executive Max Hodak stated that early clinical testing demonstrated immediate visual perception of localized light patterns during initial calibration sessions. The company confirmed that multi-center clinical trials will expand across leading academic ophthalmology centers throughout the United States and Europe in early 2027.

Vision researchers, prospective clinical trial participants, and biomedical engineers can review technical microchip specifications, surgical protocols, and peer-reviewed clinical data publications at science.xyz. Science Corporation stated that comprehensive thirty-day post-implantation visual acuity results will be presented at the upcoming international bioelectronics symposium in San Francisco. Additional patient registry enrollment guidelines will be published on clinical trial portals next month.